Tom Houben

2.1k citations

44 papers · 1.5k · 2 hit papers · h-index 17

Impact in

Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism
Epidemiology top 10%
- Liver Disease Diagnosis and Treatment
- Autophagy in Disease and Therapy

Papers in

Epidemiology 15
- Liver Disease Diagnosis and Treatment 15
Physiology 8
- Lysosomal Storage Disorders Research 5

Co-authors: Ronit Shiri‐Sverdlov (39 shared papers)Tulasi Yadati (8 shared papers)Albert V. Bitorina (10 shared papers)Yvonne Oligschlaeger (21 shared papers)Marten H. Hofker (10 shared papers)Sofie M. A. Walenbergh (13 shared papers)Tim Hendrikx (13 shared papers)Marion J. Gijbels (12 shared papers)
Journals: Scientific Reports (4 papers)Frontiers in Immunology (3 papers)Journal of Lipid Research (3 papers)Cells (2 papers)FEBS Journal (2 papers)
Partner nations: Netherlands Germany Belgium

In The Last Decade

Tom Houben

42 papers receiving 1.5k citations

Tom Houben's Hit Papers

align trajectories log scale

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study 2023 · 356 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2023 The Lancet
2020 Cells

Peers

Countries citing papers authored by Tom Houben

Since Specialization

Citations

This map shows the geographic impact of Tom Houben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Houben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Houben more than expected).

Fields of papers citing papers by Tom Houben

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Houben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Houben. The network helps show where Tom Houben may publish in the future.

Co-authors

The 25 scholars most cited alongside Tom Houben, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tom Houben Line = papers co-authored together Tom Houben links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study The Lancet ·Jesse Joachim Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson, H. Abdullah-Koolmees, Kathrin Blagec, Tanja Blagus, Stefan Böhringer, Anne Cambon‐Thomsen Hit paper breakdown →	2023	356
2	The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management Cells ·Tulasi Yadati, Tom Houben, Albert V. Bitorina, Ronit Shiri‐Sverdlov Hit paper breakdown →	2020	353
3	Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids Journal of Lipid Research ·Aafke W. F. Janssen, Tom Houben, Saeed Katiraei, Wieneke Dijk, Lily Boutens, Nieke van der Bolt, Zeneng Wang, Jonathan Mark Brown	2017	104
4	Inflammatory Bowel Disease: A Stressed “Gut/Feeling” Cells ·Yvonne Oligschlaeger, Tulasi Yadati, Tom Houben, Claudia Maria Condello Oliván, Ronit Shiri‐Sverdlov	2019	89
5	Bone marrow‐specific caspase‐1/11 deficiency inhibits atherosclerosis development in Ldlr−/− mice FEBS Journal ·Tim Hendrikx, Mike L. J. Jeurissen, Patrick J. van Gorp, Marion J. Gijbels, Sofie M. A. Walenbergh, Tom Houben, Rick van Gorp, Chantal C. H. Pöttgens	2015	60
6	Cathepsin D regulates lipid metabolism in murine steatohepatitis Scientific Reports ·Tom Houben, Yvonne Oligschlaeger, Tim Hendrikx, Albert V. Bitorina, Sofie M. A. Walenbergh, Patrick J. van Gorp, Marion J. Gijbels, Silvia Friedrichs	2017	54
7	The immunity–diet–microbiota axis in the development of metabolic syndrome Current Opinion in Lipidology ·Eelke T. Brandsma, Tom Houben, Jingyuan Fu, Ronit Shiri‐Sverdlov, Marten H. Hofker	2015	44
8	Plasma Cathepsin D Levels: A Novel Tool to Predict Pediatric Hepatic Inflammation The American Journal of Gastroenterology ·Sofie M. A. Walenbergh, Tom Houben, Tim Hendrikx, Mike L. J. Jeurissen, Patrick J. van Gorp, Anita C. E. Vreugdenhil, Marlou P. M. Adriaanse, Wim A. Buurman	2015	42
9	Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention Scientific Reports ·Sofie M. A. Walenbergh, Tom Houben, Sander S. Rensen, Veerle Bieghs, Tim Hendrikx, Patrick J. van Gorp, Yvonne Oligschlaeger, Mike L. J. Jeurissen	2016	37
10	Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids ·Tom Houben, Eelke T. Brandsma, Sofie M. A. Walenbergh, Marten H. Hofker, Ronit Shiri‐Sverdlov	2016	28
11	Hematopoietic overexpression of Cyp27a1 reduces hepatic inflammation independently of 27-hydroxycholesterol levels in Ldlr−/− mice Journal of Hepatology ·Tim Hendrikx, Mike L. J. Jeurissen, Veerle Bieghs, Sofie M. A. Walenbergh, Patrick J. van Gorp, Fons Verheyen, Tom Houben, Yasmin Dias Guichot	2014	28
12	Prevention of oxLDL uptake leads to decreased atherosclerosis in hematopoietic NPC1-deficient Ldlr−/− mice Atherosclerosis ·Mike L. J. Jeurissen, Sofie M. A. Walenbergh, Tom Houben, Marion J. Gijbels, Jieyi Li, Tim Hendrikx, Yvonne Oligschlaeger, Patrick J. van Gorp	2016	22
13	Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans Diabetologia ·Lingling Ding, Gijs H. Goossens, Yvonne Oligschlaeger, Tom Houben, Ellen E. Blaak, Ronit Shiri‐Sverdlov	2019	21
14	Blood-derived macrophages prone to accumulate lysosomal lipids trigger oxLDL-dependent murine hepatic inflammation Scientific Reports ·Tom Houben, Yvonne Oligschlaeger, Albert V. Bitorina, Tim Hendrikx, Sofie M. A. Walenbergh, Marie-Hélène Lenders, Marion J. Gijbels, Fons Verheyen	2017	21
15	Plasma Cathepsin D Activity Rather Than Levels Correlates With Metabolic Parameters of Type 2 Diabetes in Male Individuals Frontiers in Endocrinology ·Lingling Ding, Tom Houben, Yvonne Oligschlaeger, Albert V. Bitorina, Bart J. Verwer, Maarten E. Tushuizen, Ronit Shiri‐Sverdlov	2020	19
16	Inhibiting Extracellular Cathepsin D Reduces Hepatic Steatosis in Sprague–Dawley Rats Biomolecules ·Princy Khurana, Tulasi Yadati, Sandeep Kumar Goyal, Atul Dolas, Tom Houben, Yvonne Oligschlaeger, Anil K. Agarwal, Aditya Kulkarni	2019	19
17	Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice Frontiers in Immunology ·Tulasi Yadati, Tom Houben, Albert V. Bitorina, Yvonne Oligschlaeger, Marion J. Gijbels, Ronny Mohren, Dieter Lütjohann, Princy Khurana	2021	19
18	MSP is a negative regulator of inflammation and lipogenesis in ex vivo models of non-alcoholic steatohepatitis Experimental & Molecular Medicine ·Dipanjan Chanda, Jieyi Li, Yvonne Oligschlaeger, Mike L. J. Jeurissen, Tom Houben, Sofie M. A. Walenbergh, Ronit Shiri‐Sverdlov, Dietbert Neumann	2016	17
19	Weekly Treatment of 2-Hydroxypropyl-β-cyclodextrin Improves Intracellular Cholesterol Levels in LDL Receptor Knockout Mice International Journal of Molecular Sciences ·Sofie M. A. Walenbergh, Tom Houben, Tim Hendrikx, Mike L. J. Jeurissen, Patrick J. van Gorp, Nathalie Vaes, Steven W.M. Olde Damink, Fons Verheyen	2015	16
20	Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model PLoS ONE ·Jieyi Li, Dipanjan Chanda, Patrick J. van Gorp, Mike L. J. Jeurissen, Tom Houben, Sofie M. A. Walenbergh, J.M.H. Debets, Yvonne Oligschlaeger	2016	15

About Tom Houben

Tom Houben is a scholar working on Epidemiology, Physiology, Cell Biology, Molecular Biology and Cardiology and Cardiovascular Medicine, having authored 44 papers that have together received 1.5k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (15 papers), Cholesterol and Lipid Metabolism (7 papers), Lipid metabolism and disorders (6 papers), Lysosomal Storage Disorders Research (5 papers), Endoplasmic Reticulum Stress and Disease (4 papers), Sphingolipid Metabolism and Signaling (4 papers), Atherosclerosis and Cardiovascular Diseases (4 papers) and Gut microbiota and health (4 papers). The work is most often cited by research in Pharmacology (219 citations), Epidemiology (335 citations), Cancer Research (121 citations), Physiology (189 citations) and Cell Biology (126 citations). Tom Houben has collaborated with scholars based in Netherlands, Germany and Belgium. Frequent co-authors include Ronit Shiri‐Sverdlov, Tulasi Yadati, Albert V. Bitorina, Yvonne Oligschlaeger, Marten H. Hofker, Sofie M. A. Walenbergh, Tim Hendrikx, Marion J. Gijbels, Patrick J. van Gorp and Mike L. J. Jeurissen. Their work appears in journals such as Scientific Reports, Frontiers in Immunology, Journal of Lipid Research, Cells and FEBS Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Tom Houben

Impact in

Papers in i

In The Last Decade

Tom Houben

Tom Houben's Hit Papers

Peers

Countries citing papers authored by Tom Houben

Fields of papers citing papers by Tom Houben

All Works

About Tom Houben

Explore authors with similar magnitude of impact

Papers in